Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNeuropharmacology

A Novel Potent and Selective Histamine H3 Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, Wake-Promoting and Pro-cognitive Effects in Rodents

Noriko Hino, Toshiyuki Marumo, Makiko Kotani, Toshiharu Shimazaki, Ayaka Kaku-Fukumoto, Hirohiko Hikichi, Jun-ichi Karasawa, Yasumitsu Tomishima, Hiroko Komiyama, Emi Tatsuda, Dai Nozawa, Toshio Nakamura and Shigeyuki Chaki
Journal of Pharmacology and Experimental Therapeutics August 29, 2020, JPET-AR-2020-000185; DOI: https://doi.org/10.1124/jpet.120.000185
Noriko Hino
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiyuki Marumo
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makiko Kotani
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiharu Shimazaki
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayaka Kaku-Fukumoto
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirohiko Hikichi
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun-ichi Karasawa
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasumitsu Tomishima
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroko Komiyama
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emi Tatsuda
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dai Nozawa
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshio Nakamura
2Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeyuki Chaki
1Research Headquarters, Taisho Pharmaceutical Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: s-chaki@taisho.co.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Histamine H3 receptor antagonists/inverse agonists are known to enhance the activity of histaminergic neurons in the brain, thereby promoting arousal and cognition. Here, we report the in vitro and in vivo pharmacological profiles for a newly synthesized histamine H3 receptor antagonist/inverse agonist: [1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone monohydrochloride (enerisant hydrochloride). In vitro assays showed that enerisant was a competitive antagonist/inverse agonist with a high affinity and selectivity for human and rat histamine H3 receptors. Enerisant showed antagonist activity in vivo, as assessed using R-α-methylhistamine (a histamine H3 receptor agonist)-induced dipsogenia, and occupied the histamine H3 receptor in the frontal cortex in a dose-dependent manner. Enerisant also enhanced the extracellular levels of histamine in the posterior hypothalamus and the levels of dopamine and acetylcholine in the medial prefrontal cortex of rats. Enerisant exerted a pro-cognitive effect or reversed scopolamine-induced cognitive impairment in a social recognition test and a novel object recognition test in rats at doses at which less than 50% of the histamine H3 receptor were occupied (0.03 - 0.3 mg/kg, p.o.). In contrast, higher doses (3 - 10 mg/kg, p.o.) at which nearly all the histamine H3 receptor were occupied were needed to exert wake-promoting effects in rats. These results indicate that enerisant is a potent and selective histamine H3 receptor antagonist/inverse agonist with the potential to promote arousal and pro-cognition in rats. Moreover, the results also suggest that the histamine H3 receptor occupancy required to exert a pharmacological effect may vary, depending on the domain that is being tested.

Significance Statement Enerisant is a novel histamine H3 receptor antagonist/inverse agonist that exerts wake-promoting and pro-cognitive effects in addition to increasing the release of neurotransmitters related to these pharmacological effects in rodents. Moreover, an in vivo receptor binding study revealed that the in vivo occupancy of the histamine H3 receptor required to exert the pharmacological effects of enerisant varied, and such variations in required occupancy should be taken into account when performing dose selection in clinical studies.

  • cognition
  • histamine receptors
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 2
1 Feb 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel Potent and Selective Histamine H3 Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, Wake-Promoting and Pro-cognitive Effects in Rodents
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNeuropharmacology

Pharmacological profiles of enelisant

Noriko Hino, Toshiyuki Marumo, Makiko Kotani, Toshiharu Shimazaki, Ayaka Kaku-Fukumoto, Hirohiko Hikichi, Jun-ichi Karasawa, Yasumitsu Tomishima, Hiroko Komiyama, Emi Tatsuda, Dai Nozawa, Toshio Nakamura and Shigeyuki Chaki
Journal of Pharmacology and Experimental Therapeutics August 29, 2020, JPET-AR-2020-000185; DOI: https://doi.org/10.1124/jpet.120.000185

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherNeuropharmacology

Pharmacological profiles of enelisant

Noriko Hino, Toshiyuki Marumo, Makiko Kotani, Toshiharu Shimazaki, Ayaka Kaku-Fukumoto, Hirohiko Hikichi, Jun-ichi Karasawa, Yasumitsu Tomishima, Hiroko Komiyama, Emi Tatsuda, Dai Nozawa, Toshio Nakamura and Shigeyuki Chaki
Journal of Pharmacology and Experimental Therapeutics August 29, 2020, JPET-AR-2020-000185; DOI: https://doi.org/10.1124/jpet.120.000185
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Oxysterols and ethanol
  • P-glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at MT1 & MT2
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics